Our drug discovery efforts focus on addressing biologic targets that are implicated in the growth, resistance, recurrence,
and metastasis of cancer. This approach is now focused on Immuno-Oncology (IO) therapeutics.
The immune system is naturally programmed to seek out and destroy abnormal cells. Cancer is believed to thrive, in
part, because of a number of cellular mechanisms that aid in the evasion of immune response. Such mechanisms of
immune system evasion include masking or reducing the expression of tumor antigens to avoid detection, recruiting
T-cell suppressor cells or releasing inhibitory molecules that suppress immune activation, inducing conditions in
the tumor microenvironment that promote tumor cell proliferation and survival, and a number of other factors.
Immuno-oncology therapies that overcome immune suppression by stimulating responses directed to cancer cells may be
a powerful means of counteracting the cellular mechanisms that enable the growth and spread of tumors. Immuno-oncology
agents are rapidly emerging as a potential path to durable and long-lasting responses in certain patients.
By addressing the fundamental biology underlying cancer’s growth, resistance, recurrence, and metastasis, our novel therapeutic
candidates are intended to improve patient outcomes and lead to more durable survival.